Jacob Maddux, MD
Allergy & Immunology · Surprise, AZNPI 1760839211
Payments from drug & device makers
Across 545 payments — averaging $159.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$29K
- Regeneron Healthcare Solutions, Inc.$23K
- Genentech USA, Inc.$22K
- AstraZeneca$6K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$720
- plus $5K from 32 others
What the payments were for
- Consulting fees$14,15516%
- Speaking & faculty fees$53,52762%
- Travel & lodging$6,2137%
- Food & beverage$12,44714%
- Education$3410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 86 | $29,294 |
| Regeneron Healthcare Solutions, Inc. | 51 | $23,262 |
| Genentech USA, Inc. | 41 | $22,007 |
| AstraZeneca | 55 | $5,656 |
| GSK | 59 | $1,066 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $720 |
| Novartis | 22 | $514 |
| CSL Behring | 16 | $494 |
| Amgen | 21 | $401 |
| Optinose US, Inc. | 16 | $338 |
| Pfizer | 15 | $281 |
| Grifols USA, LLC | 9 | $270 |
| Sanofi-aventis U.S. LLC | 3 | $246 |
| Blueprint Medicines Corporation | 9 | $209 |
| Kaleo, Inc. | 8 | $209 |
| ADMA Biomanufacturing LLC | 12 | $204 |
| Incyte Corporation | 8 | $164 |
| Galderma Laboratories, L.p. | 6 | $160 |
| Biocryst US Sales Co., LLC | 6 | $146 |
| Octapharma USA, Inc. | 4 | $131 |
| LEO Pharma Inc. | 5 | $116 |
| Organon | 4 | $96 |
| Hikma Pharmaceuticals USA | 5 | $90 |
| AbbVie | 4 | $81 |
| Pharming Healthcare, Inc. | 3 | $77 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $70 |
| Phadia US Inc. | 4 | $64 |
| Boehringer Ingelheim | 2 | $55 |
| Lilly USA, LLC | 2 | $37 |
| Arcutis Biotherapeutics, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Ionis Pharmaceuticals, Inc. | 2 | $32 |
| Baxter Healthcare | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Merck | 1 | $20 |
| Seqirus USA Inc | 1 | $16 |
| Dermavant Sciences, Inc. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,683 in reported general payments places this provider in the 85th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $186,913 |
| Dupixent SyringeDupilumab | 39 | $181,911 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $42,739 |
| Spiriva RespimatTiotropium Bromide | 13 | $9,759 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,133 |
| Epinephrine | 20 | $6,334 |
| Azelastine Hcl | 176 | $5,969 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $5,470 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,887 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,599 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $3,357 |
| Tacrolimus | 23 | $2,658 |
| Ipratropium Bromide | 89 | $2,504 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,288 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $1,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $720 | $186,91325 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,066 | $53,47075 claims |
| Boehringer IngelheimSpiriva Respimat | $55 | $9,75913 claims |
| Hikma Pharmaceuticals USAEpinephrine | $90 | $6,33420 claims |
| AstraZenecaSymbicort | $5,656 | $3,88717 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $34 | $3,35711 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $15 | $51426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Surprise
- Connie HsuLitchfield Park$3.5M
- Michael ManningScottsdale$3.2M
- Neal JainGilbert$1.4M
- Jennifer HillScottsdale$418K
- Keith SaccoPhoenix$366K
- Tara CarrTucson$308K
- Cindy BauerPhoenix$265K
- Heather CassellTucson$261K
- Jean NelsonScottsdale$183K
- Kiranjit KhalsaScottsdale$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.